Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.
Department of Drug Safety Evaluation, Jiangxi Testing Center of Medical Instruments, Nanchang, 330029, China.
Eur J Pharm Sci. 2022 Nov 1;178:106281. doi: 10.1016/j.ejps.2022.106281. Epub 2022 Aug 19.
Nasopharyngeal carcinoma (NPC) is one of the major causes of death in Southern China. Due to the insidious location of NPC, the therapeutic effect of locoregionally advanced NPC is still unsatisfactory. In this work, to improve the treatment efficiency, combining DOC and JS-K to inhibit NPC cells (HNE-1) in vitro was investigated, as well as its possible mechanisms. Moreover, the in vivo effects of DOC and JS-K combination treatment were also evaluated in a xenograft model with HNE-1 cells. In vitro experiments including cell proliferation, migration ability, apoptosis, and expression levels of apoptosis-associated proteins revealed that the combination of DOC and JS-K was able to enhance antitumor effects. In vivo results further confirmed a significant treatment effect without obvious toxicity on mice. The present work provides a promising idea for the treatment of locally advanced NPC.
鼻咽癌(NPC)是中国南方地区主要的死亡原因之一。由于 NPC 的位置隐匿,局部晚期 NPC 的治疗效果仍不理想。在这项工作中,为了提高治疗效率,研究了 DOC 和 JS-K 联合抑制 NPC 细胞(HNE-1)的体外作用,以及其可能的机制。此外,还在 HNE-1 细胞的异种移植模型中评估了 DOC 和 JS-K 联合治疗的体内效果。体外实验包括细胞增殖、迁移能力、凋亡以及凋亡相关蛋白的表达水平揭示了 DOC 和 JS-K 的联合使用能够增强抗肿瘤作用。体内结果进一步证实了对小鼠的治疗效果显著,且无明显毒性。本工作为局部晚期 NPC 的治疗提供了一个有前途的思路。